Michelsen Laboratory

Inflammatory bowel diseases (IBD) are characterized by chronic or recurring inflammation of the gastrointestinal tract. IBD is thought to result from an overactive and continuous immune response to intestinal microbiota, including commensal and pathogenic bacteria, in a genetically susceptible host. IBD affects an estimated 1.4 million Americans. The Michelsen Laboratory is studying the underlying mechanisms that lead to the development of chronic inflammatory diseases such as IBD and colon cancer.

The Michelsen Laboratory is affiliated with the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, the Department of Medicine and the Department of Biomedical Sciences.


Learn more about work at the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute by watching the video: IBD 360: Changing the Paradigm.